Related Experiment Video
Updated: Aug 14, 2026

Isolation of Primary Patient-specific Aortic Smooth Muscle Cells and Semiquantitative Real-time Contraction Measurements In Vitro
Published on: February 15, 2022
Goniothalamin induces apoptosis in vascular smooth muscle cells
K M Chan1, N F Rajab, M H A Ishak
1Department of Biomedical Science, Faculty of Allied Health Sciences, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300 Kuala Lumpur, Malaysia.
Abstract:
Restenosis represents a major impediment to the success of coronary angioplasty. Abnormal proliferation of vascular smooth muscle cells (VSMCs) has been shown to be an important process in the pathogenesis of restenosis. A number of agents, particularly rapamycin and paclitaxel, have been shown to impact on this process. This study was carried out to determine the mechanisms of cytotoxicity of goniothalamin (GN) on VSMCs. Results from MTT cytotoxicity assay showed that the IC(50) for GN was 4.4 microg/ml (22 microM), which was lower compared to the clinically used rapamycin (IC(50) of 25 microg/ml [27.346 microM]). This was achieved primarily via apoptosis where up to 25.83 +/- 0.44% of apoptotic cells were detected after 72 h treatment with GN. In addition, GN demonstrated similar effects as rapamycin in inhibiting VSMCs proliferation using bromodeoxyuridine (BrdU) cell proliferation assay after 72 h treatment at IC(50) concentration (p > 0.05). In order to understand the mechanisms of GN, DNA damage detection using comet assay was determined at 2h post-treatment with GN. Our results showed that there was a concentration-dependent increase in DNA damage in VSMCs prior to cytotoxicity. Moreover, GN effects were comparable to rapamycin. In conclusion, our data show that GN initially induces DNA damage which subsequently leads to cytotoxicity primarily via apoptosis in VSMCs.
Insights
Goniothalamin (GN) induces DNA damage and apoptosis in vascular smooth muscle cells (VSMCs), offering a potential therapeutic strategy for restenosis. Its cytotoxicity is more potent than rapamycin, suggesting promise in cardiovascular treatments.
Area of Science:
- Cardiovascular Biology
- Pharmacology
- Cell Biology
Background:
- Restenosis, a complication of coronary angioplasty, is driven by vascular smooth muscle cell (VSMC) proliferation.
- Rapamycin and paclitaxel are established agents impacting VSMC proliferation in restenosis.
- Understanding novel therapeutic mechanisms for restenosis is crucial.
Purpose of the Study:
- To investigate the cytotoxic mechanisms of goniothalamin (GN) on VSMCs.
- To compare the efficacy of GN with rapamycin in inhibiting VSMC proliferation and inducing cytotoxicity.
- To elucidate the initial cellular events triggered by GN exposure.
Main Methods:
- MTT cytotoxicity assay to determine IC(50) values.
- Bromodeoxyuridine (BrdU) cell proliferation assay to assess proliferation inhibition.
- Comet assay to detect DNA damage post-treatment.
- Flow cytometry to quantify apoptotic cells.
Main Results:
- Goniothalamin (GN) exhibited a lower IC(50) (4.4 microg/ml) than rapamycin (25 microg/ml) in VSMCs.
- GN induced significant apoptosis in VSMCs (25.83% at 72h).
- GN demonstrated comparable inhibition of VSMC proliferation to rapamycin.
- A concentration-dependent increase in DNA damage was observed prior to GN-induced cytotoxicity.
Conclusions:
- Goniothalamin (GN) induces DNA damage in VSMCs, leading to apoptosis and cytotoxicity.
- GN shows potential as a therapeutic agent for restenosis, with higher potency than rapamycin.
- The findings provide insights into the anti-restenosis mechanisms of GN.
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Intracellular Signaling Affects Focal Adhesions
Some...
Vascular Spasm
Apoptosis

